Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib Maintenance in Advanced NSCLC
NCT03769805Phase 2Unknown
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jun 2019
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in non-small cell lung cancer (NSCLC), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Progression-Free Survival at 5 month. Status: unknown.
02
Drugs
anlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03769805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03769805.